



Proteomics International

LABORATORIES LTD

Media Release

3 June 2019

ASX code: PIQ

Proteomics International and PromarkerD at BIO Conference saying the 30 million diabetics in the USA deserve to know their future kidney disease status

- PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years
- The ground-breaking PromarkerD clinical data was first launched at the *American Diabetes Association Annual Scientific Sessions 2017* and published in the respected journal *Diabetes Care*
- PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its independent industry report titled *Biomarkers Enabling Diabetes and Obesity Management*.

PHILADELPHIA, USA, 3 JUNE 2019 - Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) will have a stand #2349 at the *BIO International Convention* (Philadelphia, June 3-6, 2019).

PromarkerD is a blood test that can diagnose and predict whether a patient will develop diabetic kidney disease. PromarkerD can predict the onset of diabetic kidney disease before clinical symptoms appear.

Proteomics International which is based in Perth, Australia, will be using the BIO opportunity to meet with partners for their US roll-out as part of their global expansion that now includes Mexico and the EU.

“PromarkerD is world-beating technology and needs to get into the hands of specialists and physicians to stem the tsunami of kidney disease which is causing over 40,000 deaths per year in the US, with related healthcare spending exceeding US\$100 billion annually.”

“There is nothing else like PromarkerD available – it’s the world's leading predictive test for diabetic kidney disease according to analysts in our sector,” said Chuck Morrison, Proteomics International's Head of Business Development, based in Boston.

He said the test will also make a major difference for insurance companies because it will cut dramatically the number of people who are unaware they have progressive kidney disease so they can do something about it immediately, and so reduce treatments costs.

“The US population with diabetes deserve to know their kidney disease status.”

PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its independent industry report titled *Biomarkers Enabling Diabetes and Obesity Management*.

PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

The Australian delegation to 2019's BIO is the largest to date, and will be among the top ten largest in attendance, alongside 17,000 biotechnology and pharma leaders from over 70 countries. The Western Australian 'Think Perth' delegation, is led by the State's Deputy Premier and Minister for Health, Hon Roger Cook, and Professor Peter Klinken, Chief Scientist of Western Australia.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

ENDS

About PromarkerD (www.PromarkerD.com)

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years.

PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

Further information is available through the PromarkerD web portal.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier
[Public Relations & Media Contact]
Digital Mantra Group
T: +61 2 8218 2144 or +1 415-951-3228
E: team@dmgpr.com

Chuck Morrison
Head of Business Development
Proteomics International
T: +1 617 331 2975
E: c.morrison@proteomicsinternational.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com